ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2309건의 자료가 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 48 | Unknown status | Urine Alkalinisation to Prevent AKI in COVID-19 | Covid19 | Drug: Sodium Bicarbonate 150Meq/L/D5W Inj | Phase 3 | Guy's and St Thomas' NHS Foundation Trust | OTHER | 80 | All | 18 Years | Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom |
| 47 | Withdrawn | Use of a Combined Regimen of Fluoxetine, Prednisolone and Ivermectin in the Treatment of Mild COVID-19 to Prevent Disease Progression Progression in Papua New Guinea | COVID-19 | Drug: Combination regimen: Fluoxetine, Prednisolone, Ivermectin Drug: Combination regimen: Albendazole, Vitamin C |
Phase 3 | Oriol Mitja, National Department of Health, Papua New Guinea, Fundacion FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promocion de la Salud y la Ciencia | OTHER | 0 | All | 18 Years ~ 99 Years | |
| 46 | Active, not recruiting | Use of BCG Vaccine as a Preventive Measure for COVID-19 in Health Care Workers | COVID 19 Vaccine | Biological: BCG vaccine Biological: 0.9% sodium chloride (NaCl) saline solution |
Phase 2 | Universidade Federal do Rio de Janeiro, Ministry of Science and Technology, Brazil | OTHER | 752 | All | 18 Years | Universidade Federal do Rio de Janeiro, Rio De Janeiro, RJ, Brazil |
| 45 | Unknown status | Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia | Covid-19 | Drug: Bromhexine Oral Tablet and/or hydroxychloroquine tablet | Phase 4 | General and Teaching Hospital Celje | OTHER | 90 | All | 19 Years | SB Celje, Celje, Slovenia |
| 44 | Terminated | Use of Convalescent Plasma for COVID-19 | COVID | Biological: Convalescent Plasma | Phase 2 | Northside Hospital, Inc. | OTHER | 8 | All | 18 Years | Northside Hospital, Atlanta, Georgia, United States |
| 43 | Enrolling by invitation | Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection | Interstitial Lung Disease | Procedure: Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF) Device: Centricyte 1000 Procedure: IV Deployment Of cSVF In Sterile Normal Saline IV Solution Drug: Liberase Enzyme (Roche) Drug: Sterile Normal Saline for Intravenous Use |
Early Phase 1 | Black Tie Medical, Inc., Robert W. Alexander, MD | INDUSTRY | 10 | All | 18 Years ~ 90 Years | Robert W. Alexander, MD, FICS, LLC, Stevensville, Montana, United States |
| 42 | Unknown status | Use of Desferal for Prevention of ARDS in Hospitalised Cases Documented With Covid 19 Infection | Covid 19 | Drug: Desferal 500 MG Injection | Phase 4 | Hesham Al-Inany | OTHER | 200 | All |
